Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Formycon AG
0W4NCurrent price
51.5 EUR
+0.4 EUR (+0.78%)
Last closed
51.8 EUR
Company
www.formycon.com
ISIN
DE000A1EWVY8
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
913 985 792 EUR
Yield for 12 month
-15.97 %
1Y
3Y
5Y
10Y
15Y
0W4N
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany. Address: Fraunhoferstrasse 15, Planegg, Germany, 82152
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
81.15 EURP/E ratio
12.8784Dividend Yield
–Current Year
+77 491 893 EUR
Last Year
+42 385 361 EUR
Current Quarter
+26 822 352 EUR
Last Quarter
+33 817 927 EUR
Current Year
+23 243 778 EUR
Last Year
+12 040 286 EUR
Current Quarter
+1 902 987 EUR
Last Quarter
+5 654 107 EUR
Key Figures 0W4N
1 year
3 years
5 years
10 years
EBITDA
-24 381 780 EUR
Operating Margin TTM
PE Ratio
12.8784
Return On Assets TTM
-1.69 %
PEG Ratio
–
Return On Equity TTM
12.73 %
Wall Street Target Price
81.15 EUR
Revenue TTM
60 640 279 EUR
Book Value
32.55 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-38.6 %
Dividend Yield
–
Gross Profit TTM
1 003 357 EUR
Earnings per share
4.02 EUR
Diluted Eps TTM
4.02 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-98.2 %
Profit Margin
105.09 %
Dividend Analytics 0W4N
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0W4N
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
385:383
Payout Ratio
–
Last Split Date
08.11.2013
Dividend Date
–
Stock Valuation 0W4N
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
12.8784
Forward PE
–
Enterprise Value Revenue
14.8732
Price Sales TTM
15.0723
Enterprise Value EBITDA
13.9762
Price Book MRQ
1.6208
Financials 0W4N
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0W4N
For 52 weeks
37.55 EUR
67.62 EUR
50 Day MA
52.04 EUR
Shares Short Prior Month
–
200 Day MA
49.9 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart